Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Glioma Undergoing Surgery

Trial Profile

A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Glioma Undergoing Surgery

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tozuleristide (Primary)
  • Indications Glioma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Blaze Bioscience
  • Most Recent Events

    • 09 May 2019 According to a Blaze Bioscience media release, results from the study have been published in the peer-reviewed journal Neurosurgery.
    • 09 May 2019 Results presented in a Blaze Bioscience media release.
    • 05 Jun 2018 Results (n=42) evaluating PK parameters in 2 clinical studies (NCT02234297 and NCT02462629) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top